Description: IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral thin film products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, and INT0040/2014. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Insud Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Home Page: www.intelgenx.com
IGX Technical Analysis
6420 Abrams
Montreal,
QC
H4S 1Y2
Canada
Phone:
514 331 7440
Officers
| Name | Title |
|---|---|
| Dr. Horst G. Zerbe | Chairman, CEO & Chairman of Scientific Advisory Board |
| Mr. André Godin C.A., CPA, CPA, CA | Pres & CFO |
| Ms. Nadine Paiement | Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp |
| Dr. Dana Matzen | VP of Bus. & Corp. Devel. of IntelGenx Corp |
| Stephen Kilmer | Investor Relations Officer |
| Dr. Rodolphe Obeid Ph.D. | VP of Operations - IntelGenx Corp |
| Mr. Tommy Kenny J.D., L.L.B., M.Sc. | VP of Intellectual Property & Legal Affairs and Gen. Counsel of IntelGenx Corp |
| Ms. Ingrid Zerbe | Corp. Sec. |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.6167 |
| Price-to-Sales TTM: | 51.5593 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |